New combo therapy aims to shrink bladder tumors before surgery

NCT ID NCT06394570

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 30 times

Summary

This study tests a combination of the drug enfortumab vedotin and targeted radiation before bladder removal surgery in people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. About 19 participants will receive different schedules of the drug and radiation to find the safest and most effective approach. The main goal is to see how many patients have no cancer left in the bladder at the time of surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

UT Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

BLADDER CANCER